Sigilon Therapeutics, Inc. (SGTX) financial statements (2022 and earlier)

Company profile

Business Address 100 BINNEY STREET
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:123,400
Cash and cash equivalents107,143
Short-term investments16,213
Other undisclosed cash, cash equivalents, and short-term investments44
Restricted cash and investments250
Receivables59
Other undisclosed current assets2,685
Total current assets:126,394
Noncurrent Assets
Operating lease, right-of-use asset12,863
Property, plant and equipment3,994
Restricted cash and investments1,118
Total noncurrent assets:17,975
TOTAL ASSETS:144,369
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,286
Accounts payable2,344
Accrued liabilities871
Employee-related liabilities3,071
Debt3,334
Other undisclosed current liabilities25,268
Total current liabilities:34,888
Noncurrent Liabilities
Long-term debt and lease obligation26,988
Long-term debt, excluding current maturities18,411
Operating lease, liability8,577
Other undisclosed noncurrent liabilities(3,244)
Total noncurrent liabilities:32,321
Total liabilities:67,209
Stockholders' equity
Stockholders' equity attributable to parent77,160
Common stock32
Additional paid in capital290,377
Accumulated other comprehensive loss(10)
Accumulated deficit(213,239)
Total stockholders' equity:77,160
TOTAL LIABILITIES AND EQUITY:144,369

Income statement (P&L) ($ in thousands)

12/31/2021
Revenues9,599
Revenue from related parties9,504
Gross profit:9,599
Operating expenses(85,235)
Operating loss:(75,636)
Nonoperating expense(1,675)
Interest and debt expense(1,988)
Loss before gain (loss) on sale of properties:(79,299)
Other undisclosed net income1,988
Net loss available to common stockholders, diluted:(77,311)

Comprehensive Income ($ in thousands)

12/31/2021
Net loss:(77,311)
Other comprehensive loss(10)
Comprehensive loss, net of tax, attributable to parent:(77,321)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: